IDH2 gene mutation (RealTime IDH2 Assay)
Jump to navigation
Jump to search
Indications
- refractory acute myeloid leukemia (AML)
- mutations in IDH2 gene confer eligibility for enasidenib (Idhifa)
- evaluation of gliomas (CPT)
- eligibility for vorasidenib (FDA-approval pending)
More general terms
Additional terms
References
- ↑ FDA News Release. August 1, 2017 FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm569421.htm